The Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) have announced a new coordinated pathway intended to speed Medicare coverage for FDA “breakthrough” devices—an important development for GI innovation. The proposed model would align evidence expectations across the two agencies and create a more predictable route from FDA marketing authorization to Medicare payment.
Under this approach, certain Class II and III devices that receive Breakthrough Device designation could qualify for earlier Medicare coverage if manufacturers generate data that address both FDA safety/effectiveness and CMS “reasonable and necessary” standards. The agencies envision closer collaboration during clinical study design and expanded use of real-world evidence after approval. For GI, this could affect novel endoscopic tools, advanced imaging platforms, digital diagnostics, and other technologies that meet breakthrough criteria.
For ASGE members, the proposal is a mixed but promising development. On the positive side, shorter coverage lags could improve patient access to clinically valuable devices and reduce financial uncertainty for practices and ASCs considering adoption. At the same time, expectations for Medicare-relevant data, post-market evidence collection, and potential time-limited coverage could influence how and where new devices are used.
CMS Press Release
FDA Press Release